Gavira Juan J, Herreros Jesús, Perez Ana, Garcia-Velloso María José, Barba Joaquín, Martin-Herrero Francisco, Cañizo Consuelo, Martin-Arnau Ana, Martí-Climent Josep M, Hernández Milagros, López-Holgado Natalia, González-Santos José María, Martín-Luengo Cándido, Alegria Eduardo, Prósper Felipe
Department of Cardiology and Cardiovascular Surgery, Clínica Universitaria, Universidad de Navarra, Navarra, Spain.
J Thorac Cardiovasc Surg. 2006 Apr;131(4):799-804. doi: 10.1016/j.jtcvs.2005.11.030.
To determine the feasibility and safety of skeletal myoblast transplantation in patients with chronic myocardial infarction undergoing coronary artery bypass grafting.
Twelve patients with a previous myocardial infarction and ischemic coronary artery disease underwent treatment with coronary artery bypass grafting surgery and intramyocardial injection of autologous skeletal myoblasts cultured with autologous serum. Global and regional cardiac function was assessed by echocardiogram. Fluorine 18 fluorodeoxyglucose and nitrogen 13-ammonia positron emission tomography studies were used to determine cardiac viability and perfusion. A group of historical control patients (n = 14) treated with coronary artery bypass grafting surgery without myoblast transplantation was analyzed.
The left ventricular ejection fraction improved from 35.5% +/- 2.3% (mean +/- SEM) before surgery to 55.1% +/- 8.2% at 12 months (P < .01) in the myoblast group and from 33.6% +/- 9.3% to 38.6% +/- 11% in the control group. Regional contractility also improved in the myoblast group, particularly in cardiac segments treated with skeletal myoblasts (wall motion score index: 3.02 +/- 0.17 at baseline vs 1.36 +/- 0.14 at 12 months; P < .0001). Quantitative fluorine 18-fluorodeoxyglucose and nitrogen 13-ammonia positron emission tomography showed an increase in viability and perfusion 12 months after surgery both globally and in segments treated with myoblasts (P = .012 and P = .004). Skeletal myoblast implantation was not associated with adverse events or an increased incidence of cardiac arrhythmias.
In patients with previous myocardial infarction, treatment with skeletal myoblasts in conjunction with coronary artery bypass is safe and feasible and is associated with an increased global and regional left ventricular function, improvement in viability, and perfusion of cardiac tissue and no significant incidence of arrhythmias.
确定在接受冠状动脉搭桥术的慢性心肌梗死患者中进行骨骼肌成肌细胞移植的可行性和安全性。
12例既往有心肌梗死和缺血性冠状动脉疾病的患者接受了冠状动脉搭桥手术,并经心内注射用自体血清培养的自体骨骼肌成肌细胞。通过超声心动图评估整体和局部心脏功能。使用氟18氟脱氧葡萄糖和氮13 - 氨正电子发射断层扫描研究来确定心肌活力和灌注情况。分析了一组接受冠状动脉搭桥手术但未进行成肌细胞移植的历史对照患者(n = 14)。
成肌细胞组左心室射血分数从术前的35.5%±2.3%(均值±标准误)提高到12个月时的55.1%±8.2%(P <.01),对照组从33.6%±9.3%提高到38.6%±11%。成肌细胞组的局部收缩力也有所改善,特别是在接受骨骼肌成肌细胞治疗的心脏节段(室壁运动评分指数:基线时为3.02±0.17,12个月时为1.36±0.14;P <.0001)。定量氟18 - 氟脱氧葡萄糖和氮13 - 氨正电子发射断层扫描显示,术后12个月时,整体及成肌细胞治疗节段的心肌活力和灌注均增加(P =.012和P =.004)。骨骼肌成肌细胞植入与不良事件或心律失常发生率增加无关。
在既往有心肌梗死的患者中,骨骼肌成肌细胞联合冠状动脉搭桥治疗是安全可行的,且与整体和局部左心室功能增加、心肌活力改善、心脏组织灌注增加以及心律失常无显著发生率相关。